The most recent round of grants by the California Institute for Regenerative Medicine (CIRM) demonstrates – again – where the future of stem cell research lies. As documented in a previous publication on this website, since its first round of grants to specific research projects in 2007, CIRM has been steadily moving away from its […]
Testimony of David A. Prentice, Ph.D., February 7-8, 2013 The following is the written testimony of Dr. Prentice before a Joint Meeting of the Committee on Public Health and Welfare, Kansas Senate and the Committee on Health and Human Services, Kansas House.
A major New England biotech company recently announced that it would begin the process that it hopes will result in the first clinical trial using induced pluripotent stem cells (iPSCs). This is hardly surprising, as the discovery, by Shinya Yamanaka, of the process to produce embryonic-like, fully pluripotent stem cells from ordinary somatic (body) cells has […]
This paper examines the funding pattern of the California Institute for Regenerative Medicine, an institution which characterizes itself as the “largest source of funding for stem cell research outside the NIH.” Tarne demonstrates that funding has moved from grants directed primarily towards embryonic stem cell research toward primarily ethical stem cells research – which has been the only stem cell research to date to result in positive treatments for illnesses.
A recent study from researchers at the University of Washington announced a major step forward in the treatment of genetic diseases and specifically in treating Down syndrome patients. Down syndrome occurs when there is an extra copy of chromosome 21 (hence its alternative name, Trisomy 21) in the individual’s genetic makeup, causing the physical and mental […]
The Nobel Prize for Medicine awarded to Japan’s Shinya Yamanaka last month is a thoroughly deserved recognition of his groundbreaking work in regenerative medicine, work that just five years ago forever changed the way stem cell research is conducted around the globe. It is also welcome recognition for a man who took seriously the ethical […]
Two recent developments involving the California Institute for Regenerative Medicine (CIRM) again serve to underscore the reality that adult and other non-embryonic avenues of stem cell research are advancing at a far more dramatic pace toward providing actual therapeutic benefits for patients than is human embryonic stem cell research (hESCR).